Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 24.
doi: 10.1097/MOG.0000000000001127. Online ahead of print.

Potassium-competitive acid blockers

Trevor A Davis  1 , C Prakash Gyawali  2
Affiliations

Potassium-competitive acid blockers

Trevor A Davis et al. Curr Opin Gastroenterol. .

Abstract

Purpose of review: Acid suppression is the mainstay of management of common foregut disorders, including gastroesophageal reflux disease (GERD), peptic ulcer disease and Helicobacter pylori infection. Drawbacks of standard management with proton pump inhibitors (PPIs) include acid lability requiring enteric coating, slow onset of effect, lack of suppression of nocturnal acid breakthrough, and need for administration before meals.

Recent findings: Potassium-competitive acid blockers (PCABs) are a novel class of acid suppressants that are effective in the management of symptomatic and erosive GERD, peptic ulcer disease and H. pylori infection. Administration before meals is not needed, and these agents achieve profound acid suppression right from the first dose, with control of daytime as well as nocturnal acid. In randomized controlled trials, PCABs are noninferior and often superior to PPIs, especially in healing of advanced grade esophagitis and eradication of treatment-naive as well as refractory H. pylori. The safety profile of PCABs over 10 years of use is reassuring, although profound acid suppression may contribute to hypergastrinemia and increased risk of gastrointestinal infections.

Summary: As PCABs become available in many countries around the globe, real-world use will allow further research to determine the clinical niche of these acid-suppressive agents.

Keywords: acid suppression; gastroesophageal reflux disease; peptic ulcer disease.

PubMed Disclaimer

References

    1. Gyawali CP. Proton pump inhibitors in gastroesophageal reflux disease: friend or foe. Curr Gastroenterol Rep 2017; 19:46.
    1. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798–1810.
    1. Delshad SD, Almario CV, Chey WD, et al. Prevalence of Gastroesophageal Reflux Disease and Proton Pump Inhibitor-Refractory Symptoms. Gastroenterology 2020; 158:1250.e2–1261.e2.
    1. Scarpignato C, Hunt RH. Editorial: potassium-competitive acid blockers for acid-related diseases-tegoprazan, a new kid on the block. Aliment Pharmacol Ther 2019; 50:960–962.
    1. Spechler SKJ, Dunbar K, et al. American Foregut Society White Paper Report on the use of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Foregut 2025. (in press).

LinkOut - more resources